PHS
ALNY icon

PFM Health Sciences’s Alnylam Pharmaceuticals ALNY Stock Holding History

PFM Health Sciences’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-72,220
Closed -$23.6M – 74
2025
Q2 		$23.6M Sell
72,220
-14,925
-17% -$4.13M 2% 17
2025
Q1 		$23.5M Buy
+87,145
New +$22.4M 1.71% 19
2020
Q2 		– Sell
-81,804
Closed -$8.9M – 77
2020
Q1 		$8.9M Buy
+81,804
New +$9.44M 0.73% 45

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

PFM Health Sciences's ALNY Position: Q3 2025 in Review

PFM Health Sciences sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2025, closing a stake of 72,220 shares — an estimated $23.6M sold.

PFM Health Sciences first reported a position in ALNY in Q1 2020 and held it in 3 quarters. The position peaked at $23.6M in Q2 2025. 821 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

  • PFM Health Sciences reported no remaining Alnylam Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • PFM Health Sciences sold 72,220 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $23.6M.
  • PFM Health Sciences first reported a position in Alnylam Pharmaceuticals in Q1 2020 and held it in 3 quarters.
  • PFM Health Sciences's Alnylam Pharmaceuticals position peaked at $23.6M in Q2 2025.
  • 821 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on PFM Health Sciences's 13F filing for Q3 2025, filed 14 Nov 2025.